Metabolism of (+)-1,4-dihyclro-7-(trans-3-methoxy-4-methylannino-1- pyrrolidinyl)-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid (voreloxin; Formerly SNS-595), a novel replication-dependent DNA-damaging agent

Drug Metabolism and Disposition

Volumn 37, Issue 3, 2009, Pages 594-601

  Evanchik, Marc J ^a,b   Allen, Darin ^a,c   Yoburn, Josh C ^a   Silverman, Jeffrey A ^a   Hoch, Ute ^a,d  

^a Sunesis Pharmaceuticals Inc   (United States)

^b ChemoCentryx Inc   (United States)

^c GILEAD SCIENCES   (United States)

^d NEKTAR THERAPEUTICS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AG 7352; ANTINEOPLASTIC AGENT; CYTOCHROME P450; DRUG METABOLITE; GLUCURONOSYLTRANSFERASE; SNS 595; UNCLASSIFIED DRUG; VORELOXIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; DEALKYLATION; DRUG BILE LEVEL; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG CONJUGATION; DRUG EXCRETION; DRUG FECES LEVEL; DRUG GLUCURONIDATION; DRUG HALF LIFE; DRUG ISOLATION; DRUG OXIDATION; DRUG STABILITY; DRUG STRUCTURE; DRUG URINE LEVEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; ISOTOPE LABELING; LIVER MICROSOME METABOLISM; MALE; MONKEY; NONHUMAN; PRIORITY JOURNAL; RAT; SINGLE DRUG DOSE; SPECIES DIFFERENCE; TANDEM MASS SPECTROMETRY;

ANIMALS; AREA UNDER CURVE; BILE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DNA DAMAGE; DNA REPLICATION; MALE; NAPHTHYRIDINES; RATS; RATS, SPRAGUE-DAWLEY; TANDEM MASS SPECTROMETRY; THIAZOLES;

RATTUS;

EID: 61449152953     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.108.023432     Document Type: Article

References (23)

1. Bailey MJ and Dickinson RG (2003) Acyl glucuronide reactivity in perspective: biological consequences. Chem Biol Interact 145:117-137.
2. Burris H, Krug L, Shapiro G, Fidias P, Crawford J, Reiman T, Michelson G, Berman C, Mahadocon K, Hoch U, et al. (2007) SNS-595: Preliminary results of two phase 2 second line studies in lung cancer [abstract], in ECCO 14 European Cancer Conference; 2007 September 23-27; Barcelona, Spain.
3. Dalvie DK, Khosla NB, Navetta KA, and Brighty KE (1996) Metabolism and excretion of trovafloxacin, a new quinolone antibiotic, in Sprague-Dawley rats and beagle dogs. Effect of bile duct cannulation on excretion pathways. Drug Metab Dispos 24:1231-1240.
4. Fisher MB, Campanale K, Ackermann BL, VandenBranden M, and Wrighton SA (2000) In vitro glucuronidation using human liver microsomes and the pore-forming peptide alamethicin. Drug Metab Dispos 28:560-566.
5. Frank SK, Mathiesen DA, Szurszewski M, Kuffel MJ, and Ames MM (1989) Preclinical pharmacology of the anthrapyrazole analog oxantrazole (NSC-349174, piroxantrone). Cancer Chemother Pharmacol 23:213-218.
6. Hansen MB, Nielsen SE, and Berg K (1989) Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill. J Immunol Methods 119:203-210.
7. Hoch U, Evanchik MJ, and Silverman JA (2005) CYP450 inhibition, induction, metabolism and routes of elimination of SNS-595, a novel cell cycle inhibitor currently in Phase I clinical trials [abstract]. AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics: Discovery, Biology, and Clinical Applications; 2005 Nov 14-18; Philadelphia, PA, pp C221. American Association for Cancer Research, Philadelphia, PA.
8. Hoch U and Silverman JA (2007) SNS-595 demonstrates predictable, dose-proportional pharmacokinetics in three Phase 1 clinical studies [abstract]. AAPS Annual Meeting and Exposition; 2007 Nov 11-15; San Diego, CA, pp 3658. American Association of Pharmaceutical Scientists, Arlington, VA.
9. Hyneck ML, Munafo A, and Benet LZ (1988) Effect of pH on acyl migration and hydrolysis of tolmetin glucuronide. Drug Metab Dispos 16:322-324.
10. Lancet J, Kantarjian H, Ravandi F, Bastien S, Alino K, Michelson G, and Karp J (2007) SNS-595 demonstrates clinical responses in a Phase 1 study in acute leukemia [abstract]. Blood (ASH Annual Meeting Abstracts); 2007 Dec 8-11; Atlanta, GA, pp 442. American Society of Hematology, Washington, DC.
11. Miners JO, Smith PA, Sorich MJ, McKinnon RA, and Mackenzie PI (2004) Predicting human drug glucuronidation parameters: application of in vitro and in silico modeling approaches. Annu Rev Pharmacol Toxicol 44:1-25.
12. Mosmann T (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65:55-63.
13. Okada T, Sato H, Tsuji T, Tsushima T, Nakai H, Yoshida T, and Matsuura S (1993) Synthesis and structure-activity relationships of 7-(3′-amino- 4′-methoxypyrrolidin-1′-yl)-1-cyclopropyl-6,8-difluoro-l, 4-dihydro-4-oxoquinoline-3-carboxylic acids. Chem Pharm Bull (Tokyo) 41:132-138.
14. Ramji JV, Austin NE, Boyle GW, Chalker MH, Duncan G, Fairless AJ, Hollis FJ, McDonnell DF, Musick TJ, and Shardlow PC (2001) The disposition of gemifloxacin, a new fluoroquinolone antibiotic, in rats and dogs. Drug Metab Dispos 29:435-442.
15. Spahn-Langguth H and Benet LZ (1992) Acyl glucuronides revisited: is the glucuronidation process a toxification as well as a detoxification mechanism? Drug Metab Rev 24:5-47.
16. Spahn-Langguth H, Dahms M, and Hermening A (1996) Acyl glucuronides: covalent binding and its potential relevance. Adv Exp Med Biol 387:313-328.
17. Stockett D, Byl JA, Hawtin RE, Tan N, Zhu Y, Arkin MR, Yang W, McDowell RS, Osheroff N, and Fox JA (2008) SNS-595 is a potent anti-tumor agent that has a dual mechanism of action: DNA intercalation and site-selective topoisomerase II poisoning [abstract]. Proceedings of the 99th Annual Meeting of the American Association for Cancer Research; 2008 12-16 April; San Diego, CA. pp 1860, American Association for Cancer Research, Philadelphia, PA.
18. Tachibana M, Tanaka M, Masubuchi Y, and Horie T (2005) Acyl glucuronidation of fluoroquinolone antibiotics by the UDP- glucuronosyltransferase IA subfamily in human liver microsomes. Drug Metab Dispos 33:803-811.
19. Tomita K, Tsuzuki Y, Shibamori K, Tashima M, Kajikawa F, Sato Y, Kashimoto S, Chiba K, and Hino K (2002) Synthesis and structure-activity relationships of novel 7-substituted 1,4-dihydro-4-oxo-1-(2-thiazolyl)-1,8- naphthyridine-3-carboxylic acids as antitumor agents. Part 1. J Med Chem 45:5564-5575.
20. Tsuzuki Y, Tomita K, Sato Y, Kashimoto S, and Chiba K (2004a) Synthesis and structure-activity relationships of 3-substituted 1,4-dihydro-4-oxo-1-(2- thiazolyl)-1,8-naphthyridines as novel antitumor agents. Bioorg Med Chem Lett 14:3189-3193.
21. Tsuzuki Y, Tomita K, Shibamori K, Sato Y, Kashimoto S, and Chiba K (2004b) Synthesis and structure-activity relationships of novel 7-substituted 1,4-dihydro-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acids as antitumor agents. Part 2. J Med Chem 47:2097-2109.
22. Wang M and Dickinson RG (1998) Disposition and covalent binding of diflunisal and diflunisal acyl glucuronide in the isolated perfused rat liver. Drug Metab Dispos 26:98-104.
23. Williams JA, Hyland R, Jones BC, Smith DA, Hurst S, Goosen TC, Peterkin V, Koup JR, and Ball SE (2004) Drug-drug interactions for UDP-glucuronosyl transferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos 32:1201-1208.